BACK
Benj Garrett
Managing Director
New York Office | benj.garrett@torreya.com | 212.257.5807
Benj Garrett, a Managing Director at Torreya, specializes in the execution of international strategic M&A transactions in the biotechnology, pharmaceutical, and generic sectors. Since joining Torreya in 2008, Benj has participated in numerous strategic transactions including several with Japanese clients.
Benj graduated summa cum laude from NYU’s Stern School of Business, with a B.S. in finance and statistics.
Selected Transactions
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
|
| Partial sale of royalty and milestones |
|
|
$40 million
September 2016
|
|
| Sale and contribution of orphan disease asset to |
|
|
Undisclosed
May 2016
|
|
| Sale of Akarx to |
|
|
Undisclosed
March 2016
|
|
| Acquisition of Donnatal® from |
|
|
$328 million
May 2014
|
|
| Sale of ANDA portfolio to |
|
|
Undisclosed
January 2018
|
|
|
| Sale of generics portfolio to |
|
|
$18 million
August 2017
|
|
| Sale of royalties to |
|
|
$22 million
December 2016
|
|
| Sale of phase II enzyme replacement royalty |
|
|
|
Undisclosed
August 2016
|
|
|
| Sale of Zonalon® to |
|
|
Undisclosed
March 2015
|
|
| Sale of Pessac plant to |
|
|
Up to €22 million
November 2014
|
|
|
| Divestiture of certain abbreviated new drug applications to |
|
|
Up to $18 million
October 2014
|
|
| Sale of 31 abbreviated new drug applications to |
|
|
$12.5 million +
profit share December 2013
|
|
| Sale to |
|
|
|
Undisclosed
December 2013
|
|
| Sale to |
|
|
19.9% of shares +
$12 million November 2013
|
|
| Sale of Naprelan® to |
|
|
Undisclosed
November 2013
|
|
|
| Divestiture of three pediatric drugs to |
|
|
|
$28.7 million
May 2013
|
|
| Sale of Fareston® to |
|
|
$21.7 million
October 2012
|
|
|
| Divestiture of Cuvposa® to |
|
|
Undisclosed
August 2012
|
|
| Sale of dermatology specialty pharma business to |
|
|
Undisclosed
December 2010
|
|
| Sale to |
|
|
$100+ million
October 2010
|
|
| Advisor in the acquisition of six products from |
|
|
Undisclosed
July 2010
|
|
| Sale of Crinone® & Prochieve® product lines and shares to |
|
|
$92.5 million with
$47 million upfront July 2010
|
|
| Advisor to Genentech major shareholder in sale to |
|
|
$46 billion
March 2009
|